Takeda Partner Santhera Commences Phase III Trial For Duchenne Muscular Dystrophy Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Takeda disclosed recently that Swiss partner Santhera has commenced a pivotal Phase III trial for Catena/Sovrima (idebenone), which could be the first drug to treat Duchenne Muscular Dystrophy, a rare disease that affects an estimated 30,000 European and North American male patients mainly in their teens